Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Mitiglinide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPA1 | P15085 | 7/20 | 0.51 |
| ▸ | CPA3 | P15088 | 3/20 | 0.51 |
| ▸ | CPB1 | P15086 | 1/20 | 0.51 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | MME | P08473 | 1/20 | 0.46 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.44 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.43 |
| ▸ | DPP4 | P27487 | 1/20 | 0.42 |
| ▸ | LTA4H | P09960 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mitiglinide SCHEMBL9047718 | 1.00 | CPA1 (0.51) | CPA1CPA3CPB1CPB2CYP1A2 | |
| Mitiglinide SCHEMBL4703559 | 1.00 | CPA1 (0.51) | CPA1CPA3CPB1CPB2CYP1A2 | |
| Mitiglinide SCHEMBL9047726 | 1.00 | CPA1 (0.51) | CPA1CPA3CPB1CPB2CYP1A2 | |
| Mitiglinide SCHEMBL4181526 | 1.00 | CPA1 (0.51) | CPA1CPA3CPB1CPB2CYP1A2 | |
| Mitiglinide SCHEMBL14151746 | 1.00 | CPA1 (0.51) | CPA1CPA3CPB1CPB2CYP1A2 | |
| Mitiglinide SCHEMBL3226699 | 1.00 | CPA1 (0.51) | CPA1CPA3CPB1CPB2CYP1A2 | |
| Mitiglinide SCHEMBL6135224 | 1.00 | CPA1 (0.51) | CPA1CPA3CPB1CPB2CYP1A2 | |
| Mitiglinide SCHEMBL9047711 | 1.00 | CPA1 (0.51) | CPA1CPA3CPB1CPB2CYP1A2 | |
| Mitiglinide SCHEMBL2921890 | 0.99 | CPA1 (0.50) | CPA1CPA3CPB1CPB2CYP1A2 | |
| Mitiglinide SCHEMBL199175 | 0.99 | CPA1 (0.50) | CPA1CPA3CPB1CPB2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6303640-B1 | ADMINISTERING OXAZOLE OR THIAZOLE DERIVATIVE COMPOUND FOR REDUCING SIDE EFFECTS OF DIABETIC THERAPY | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-10-16 | — | — | US | claimed |
| US-6211205-B1 | ANTIDIABETIC AGENTS THAT ENHANCE INSULIN SECRETION | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-04-03 | — | — | US | claimed |
| US-10112963-B2 | Substituted bisphenyl butanoic phosphonic acid derivatives as NEP inhibitors | NOVARTIS AG (CH) | 2018-10-30 | — | — | US | disclosed |
| US-9242963-B2 | Organic compounds | NOVARTIS AG (CH) | 2016-01-26 | — | — | US | disclosed |
| US-20150210672-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2015-07-30 | — | — | US | disclosed |
| US-9017949-B2 | Method of screening for compounds useful in the treatment of insulin resistance, impaired glucose tolerance or diabetes | Arena Pharmacueticals, Inc. (US) | 2015-04-28 | — | — | US | disclosed |
| US-8933083-B2 | 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia | ARENA PHARMACEUTICALS, INC. (US) | 2015-01-13 | — | — | US | disclosed |
| US-20140288126-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2014-09-25 | — | — | US | disclosed |
| EP-1812080-B1 | GPR41 AND MODULATORS THEREOF FOR THE TREATMENT OF INSULIN-RELATED DISORDERS | ARENA PHARM INC (US) | 2014-07-09 | — | — | EP | disclosed |
| US-8507473-B2 | 3H-imidazo[4,5-b]pyridin-5-ol derivatives useful in the treatment of GPR81 receptor disorders | ARENA PHARMACEUTICALS, INC. (US) | 2013-08-13 | — | — | US | disclosed |
| US-8383827-B2 | Aryl pyridine as aldosterone synthase inhibitors | NOVARTIS AG (CH) | 2013-02-26 | — | — | US | disclosed |
| US-6133295-A | LOWERING BLOOD HEMOGLOBIN A1 LEVELS IN A MAMMAL BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER IN COMBINATION WITH AN ALPHA-GLUCOSIDASE INHIBITOR; SYNERGISTIC; USE IN DIABETES PROPHYLAXIS OR TREATMENT | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2000-10-17 | — | — | US | disclosed |
| US-6133293-A | INSULIN SENSITIVITY ENHANCER IN COMBINATION WITH OTHER ANTIDIABETICS DIFFERING FROM THE ENHANCER IN THE MECHANISM OF ACTION; POTENT DEPRESSIVE EFFECT ON DIABETIC HYPERGLYCEMIA; 2,4-THIAZOLIDINEDIONES AND OXAZOLIDINEDIONES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2000-10-17 | — | — | US | disclosed |
| US-6121295-A | TREATING DIABETIC COMPLICATIONS BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH A STATIN COMPOUND SUCH AS PRAVASTATIN | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2000-09-19 | — | — | US | disclosed |
| US-6121294-A | REDUCING THE AMOUNT OF THERAPEUTIC AGENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER IN COMBINATION WITH AN ALPHA-GLUCOSIDASE INHIBITOR AS SAID THERAPEUTIC AGENTS; SIDE EFFECT REDUCTION | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2000-09-19 | — | — | US | disclosed |
| US-6080765-A | ADMINISTERING TO A MAMMAL FOR TREATING LIPID METABOLISM DISORDERS AN INSULIN SENSITIVITY ENHANCER WITH AN ALPHA-GLUCOSIDASE INHIBITOR | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2000-06-27 | — | — | US | disclosed |
| EP-0967204-A1 | PROCESS FOR PRODUCING BENZYLSUCCINIC ACID DERIVATIVES | Kissei Pharmaceutical Co. Ltd. (JP) | 1999-12-29 | — | — | EP | disclosed |
| US-5952356-A | TREATING DIABETES IN A MAMMAL WITH AN ACTIVE MATERIAL AND A GLUCOSIDASE INHIBITOR | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-09-14 | — | — | US | disclosed |
| EP-0861666-A2 | Pharmaceutical composition for use in treatment of diabetes | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-09-02 | — | — | EP | disclosed |
| EP-0749751-A2 | Pharmaceutical composition for use in tteatment of diabetes | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10112963-B2 | Substituted bisphenyl butanoic phosphonic acid derivatives as NEP inhibitors | MME, REN, ENPP1 | CPA1 269/4885CPA3 444/4885CPB1 379/4885 |
| US-20150210672-A1 | ORGANIC COMPOUNDS | SLCO2B1, SLCO1B1, SLCO1B3 | CPA1 1593/4885CPA3 762/4885CPB1 2374/4885 |
| US-20140288126-A1 | ORGANIC COMPOUNDS | SLCO2B1, SLCO1B1, SLCO1B3 | CPA1 1593/4885CPA3 762/4885CPB1 2374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.